28, 2014 /PRNewswire/ -- Results from a retrospective analysis of patients with chronic lung disease conducted by SCIO Health Analytics and validated by leading pulmonologists demonstrated that use of a portable non-invasive open ventilation system resulted in clinically significant improvements in the modified British Medical Research Council (mMRC) dyspnea scale
and the COPD Assessment Test (CAT).
The patient was not in any pain at the time of evaluation and complained of 4/10 on the Borg Dyspnea scale
when negotiating 30 steps.
Triantafillidou C, Manali ED, Magkou C, Sotiropoulou C, Kolilekas LF, Kagouridis K, Rontogianni D, Papiris SA Medical Research Council dyspnea scale
does not relate to fibroblast foci profusion in IPF Diagn Pathol.
Medscape Dyspnea Scale
(Le Jacq Communications, 2004)
Dyspnea was quantified with the Medical Research Council (MRC) Dyspnea Scale
 and the modified Borg rating scale .
313), or a reduction of heart failure symptoms as measured by subject self-assessment on a dyspnea scale
at six and 24 hours after initiation, (p=0.
The Baseline Dyspnea Scale
(17) and the Modified Shuttle Walking test (20) require assessment by an observer interviewer.
One questionnaire was a compilation of the medical research council (MRC) dyspnea scale
, the 12-item Short Form Health Survey (SF-12, version 2), a modified American Thoracic Society (ATS) respiratory questionnaire, and additional questions about disease and smoking history, work and non-work activities missed due to breathing problems.
The primary efficacy variable in STRIDE 2 will be six-minute walk distance and secondary variables will include change in functional class, occurrence of clinical events and shortness of breath as measured by the Borg dyspnea scale
Furthermore, with a standardized dyspnea scale
, the time to complete the questionnaire ranged from 5 to 8 minutes.
Preliminary analysis of other secondary efficacy measures, including change in Borg Dyspnea Scale
rating (shortness of breath test), NYHA functional class, time to clinical worsening (as defined by death, transplant, atrial septostomy, hospitalization due to PAH, or initiation of another approved PAH therapy), and the 6MW distance at treatment day 1, did not differ significantly between the Viveta and placebo groups (p>0.
5) Various outcome measures, such as the Six Minute Walk Test (SMWT), (6) the San Diego Shortness of Breath Questionnaire, (7) and the Medical Research Council Dyspnea Scale
, (8) have been developed to help clinicians measure the implications of CVP disease on function.